In a recent study published in the journal JAMA Network Open, researchers determined new-onset diabetes, hypertension, and hyperlipidemia, all cardiometabolic disorders in adult coronavirus disease 2019 (COVID-19) patients under treatment in California, United States of America (USA) between March 2020 and June 2022.
Researchers assessed the temporal relationship between COVID-19 diagnosis and surgery time with the risk of occurrence of cardiovascular morbidity events within 30 days of surgery.
The study, recently published in The Journal of the American Medical Association, deduced that previous SARS-CoV-2 infection is associated with a statistically significant reduced hazard of breakthrough infection among recipients of both the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna) vaccines.